{"product_id":"new-risk-score-helps-predict-which-patients-with-clonal-cytopenia-will-develop-blood-cancer","title":"New Risk Score Helps Predict Which Patients With Clonal Cytopenia Will Develop Blood Cancer","description":"\u003cp\u003eResearchers studied 357 patients with clonal cytopenia of undetermined significance (CCUS). CCUS is a blood condition marked by gene mutations and low blood cell counts. CCUS does not yet meet the criteria for a blood cancer. They identified three factors that predict which patients are most likely to progress to a myeloid neoplasm, a type of blood cancer. The factors are splicing mutations (2 points), platelet count below 100×10⁹\/L (2.5 points), and having two or more mutations (3 points). These factors were combined into a Clonal Cytopenia Risk Score (CCRS) that sorted patients into low-, intermediate-, and high-risk groups. Over two years, the risk of progression was 6.4% for low-risk patients, 14.1% for intermediate-risk patients, and 37.2% for high-risk patients. The score was then validated in a separate group of 104 patients, confirming its usefulness.\u003c\/p\u003e\n\n\u003ch1\u003eNew Risk Score Helps Predict Which Patients With Clonal Cytopenia Will Develop Blood Cancer\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eWhat Is Clonal Cytopenia of Undetermined Significance?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#why-matters\"\u003eWhy This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#study-methods\"\u003eHow the Study Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#key-findings\"\u003eKey Findings: Building the Risk Score\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#validation\"\u003eValidating the Risk Score in a Second Group of Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#treatment\"\u003eTreatment Approaches and Outcomes\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations of the Study\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eIn a study of 357 patients with CCUS, three factors predicted progression to a myeloid neoplasm: splicing mutations, platelet count below 100×10⁹\/L, and two or more mutations.\u003c\/li\u003e\n\u003cli\u003eThese factors were combined into the Clonal Cytopenia Risk Score (CCRS), which sorted patients into low, intermediate, and high risk groups.\u003c\/li\u003e\n\u003cli\u003eOver two years, progression occurred in 6.4% of low-risk, 14.1% of intermediate-risk, and 37.2% of high-risk patients in that study.\u003c\/li\u003e\n\u003cli\u003eThe CCRS was validated in a separate group of 104 patients, with a c-index of 0.64, indicating moderate predictive ability.\u003c\/li\u003e\n\u003cli\u003eEven in the high-risk group, 62.8% of patients did not progress to a myeloid neoplasm within two years.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eWhat Is Clonal Cytopenia of Undetermined Significance?\u003c\/h2\u003e\n\n\u003cp\u003eClonal cytopenia of undetermined significance (CCUS) is a blood condition that sits in a gray zone between normal aging and blood cancer. Patients with CCUS have low blood cell counts (cytopenia) that doctors cannot explain, along with specific gene mutations in their blood or bone marrow. These mutations are called somatic mutations, meaning they are acquired during a person's lifetime rather than inherited.\u003c\/p\u003e\n\n\u003cp\u003eThe World Health Organization (WHO) formally defined CCUS in its fifth edition of the Classification of Haematolymphoid Tumours. To receive a CCUS diagnosis, a patient must have a myeloid-related somatic mutation with a variant allele fraction (VAF) of at least 2%. The VAF measures what percentage of a patient's blood cells carry the mutation. The patient must also have unexplained low blood cell counts but must not meet the criteria for a myeloid neoplasm (a type of blood cancer).\u003c\/p\u003e\n\n\u003cp\u003eThere are related conditions that doctors also recognize. If a patient has these mutations but normal blood counts, the condition is called clonal hematopoiesis of indeterminate potential (CHIP). A patient may have elevated monocyte counts, a specific type of white blood cell. If the patient does not have the bone marrow features of chronic myelomonocytic leukemia (CMML), the condition is called clonal monocytosis of undetermined significance (CMUS). When both cytopenia and monocytosis are present, it is called clonal cytopenia and monocytosis of undetermined significance (CCMUS).\u003c\/p\u003e\n\n\u003cp\u003eCHIP is considered an early precursor to blood cancer, but the annual risk of progression is low. Transformation to a myeloid neoplasm occurs in only 0.5% to 1% of CHIP cases each year. However, CHIP is linked to an increased risk of other health problems, especially cardio-cerebrovascular diseases (conditions affecting the heart and blood vessels in the brain).\u003c\/p\u003e\n\n\u003cp\u003eCCUS is more concerning. Patients with CCUS have a 10-fold higher likelihood of progressing to a myeloid neoplasm compared with patients who have CHIP. Specific mutation patterns play a major role in both diagnosing blood cancer and predicting disease progression. These patterns include splicing mutations, co-mutations involving the genes DNMT3A, TET2, or ASXL1 (often called DTA mutations), the total number of mutations, and the VAF level.\u003c\/p\u003e\n\n\u003ch2 id=\"why-matters\"\u003eWhy This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eDoctors are now finding more cases of CCUS because next-generation sequencing (NGS) is used more often to evaluate patients with low blood cell counts. NGS is a technology that can read the genetic code of many genes at once. As more patients receive a CCUS diagnosis, understanding who is at highest risk of progression becomes critical.\u003c\/p\u003e\n\n\u003cp\u003eCurrently, there is no established standard of care for treating CCUS. Existing therapies have low response rates. This creates an urgent need to identify high-risk patients who should be enrolled in clinical trials testing new treatments.\u003c\/p\u003e\n\n\u003cp\u003eTwo earlier risk models were developed using data from the UK Biobank, a large population-based study. The first is the Clonal Hematopoiesis Risk Score (CHRS). The CHRS includes whether a patient has CCUS, their mutation patterns, age, red blood cell measurements, and other factors. Patients with a CHRS of 12.5 or higher were classified as high-risk. Their cumulative 5-year risk of progression to a myeloid neoplasm was 24%. Patients with a CHRS between 10 and 12 (intermediate risk) had a 5-year progression rate of 2.7%. Those with a CHRS below 9.5 (low risk) had a progression rate of only 0.23%.\u003c\/p\u003e\n\n\u003cp\u003eThe second model is called MN-predict. It uses genetic data, clinical features, and blood chemistry results to provide year-by-year probabilities of progression to a myeloid neoplasm for up to 15 years.\u003c\/p\u003e\n\n\u003cp\u003eHowever, these models were built from population-based data, not from patients seen in real-world clinical practice. The researchers behind this new study wanted to develop a risk score specifically for patients diagnosed with clonal cytopenia in actual medical centers.\u003c\/p\u003e\n\n\u003ch2 id=\"study-methods\"\u003eHow the Study Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThis study was conducted by the CCUS consortium, a collaborative group of 17 academic medical centers across the United States and Europe. The study began in 2020. All patients provided written informed consent, and the research protocol was approved by the medical ethics committee of the Mayo Clinic. The study followed the ethical principles of the Declaration of Helsinki.\u003c\/p\u003e\n\n\u003cp\u003eTo be included in the study, patients had to meet several criteria:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eBe at least 18 years old\u003c\/li\u003e\n  \u003cli\u003eHave a bone marrow biopsy that did not meet the diagnostic criteria for a myeloid neoplasm\u003c\/li\u003e\n  \u003cli\u003eHave unexplained low blood cell counts\u003c\/li\u003e\n  \u003cli\u003eHave a myeloid-related somatic mutation with a VAF of at least 2%\u003c\/li\u003e\n  \u003cli\u003eNot have received any prior therapy for cytopenia at the time of CCUS diagnosis\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003ePatients who had a cytogenetic abnormality (a chromosome change) were included and classified as having CCUS, unless the chromosome change was one that specifically defines myelodysplastic syndrome (MDS). In that case, the patient was excluded from the study.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers collected real-world data on these patients, including their clinical characteristics, mutation profiles, blood counts, and outcomes over time. They then used statistical methods to identify which factors best predicted progression to a myeloid neoplasm.\u003c\/p\u003e\n\n\u003cp\u003eThe research team performed a multivariate analysis, which is a statistical method that examines multiple factors at the same time to determine which ones independently affect outcomes. They used a Cox proportional hazards model, a common statistical tool for analyzing time-to-event data, to calculate the relative importance of each risk factor.\u003c\/p\u003e\n\n\u003ch2 id=\"key-findings\"\u003eKey Findings: Building the Risk Score\u003c\/h2\u003e\n\n\u003cp\u003eThe study analyzed 357 patients with CCUS. The researchers investigated how clonality (the presence of mutated cells), cytopenia (low blood cell counts), and prognosis (likely outcomes) interacted with each other.\u003c\/p\u003e\n\n\u003cp\u003eThe multivariate analysis identified three key factors that independently predicted a higher risk of progression to a myeloid neoplasm:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSplicing mutations:\u003c\/strong\u003e Patients whose mutations affected the cellular machinery for splicing RNA (a process that helps build proteins) had a worse prognosis. This factor received a score of 2 points.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLow platelet count:\u003c\/strong\u003e Patients with a platelet count below 100×10⁹\/L (less than 100 billion platelets per liter of blood) had a worse prognosis. This factor received a score of 2.5 points.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTwo or more mutations:\u003c\/strong\u003e Patients who had at least two different mutations had a worse prognosis. This factor received a score of 3 points.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe researchers assigned point values based on the coefficients from the Cox proportional hazards model. This means that factors with a stronger association with progression received higher point values.\u003c\/p\u003e\n\n\u003cp\u003eThese three factors were combined into a single tool called the Clonal Cytopenia Risk Score (CCRS). The CCRS sorted patients into three groups:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLow risk:\u003c\/strong\u003e Score less than 2.5 points\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIntermediate risk:\u003c\/strong\u003e Score between 2.5 and less than 5 points\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHigh risk:\u003c\/strong\u003e Score of 5 points or higher\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe CCRS effectively predicted the 2-year cumulative incidence of progression to a myeloid neoplasm. Cumulative incidence means the total proportion of patients who experienced the outcome over a given time period. The results were:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLow-risk group:\u003c\/strong\u003e 6.4% of patients progressed within 2 years\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIntermediate-risk group:\u003c\/strong\u003e 14.1% of patients progressed within 2 years\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHigh-risk group:\u003c\/strong\u003e 37.2% of patients progressed within 2 years\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThese differences between the groups were highly statistically significant. The researchers used a statistical test called Gray's test, which produced a P value of less than .0001. This means there is less than a 0.01% chance that these differences occurred by random chance alone.\u003c\/p\u003e\n\n\u003cp\u003eThe high-risk group had nearly six times the rate of progression compared with the low-risk group. The intermediate-risk group had more than double the rate of the low-risk group.\u003c\/p\u003e\n\n\u003ch2 id=\"validation\"\u003eValidating the Risk Score in a Second Group of Patients\u003c\/h2\u003e\n\n\u003cp\u003eThe researchers tested the CCRS on an independent cohort of 104 patients with CCUS. This cohort was from the University of Pavia in Italy. The test aimed to confirm that the CCRS works beyond the original group of patients. An independent cohort is a separate group of patients who were not part of the original study. Using a separate group helps confirm that the results are not just specific to the first group of patients.\u003c\/p\u003e\n\n\u003cp\u003eThe CCRS performed well in this validation group. The researchers measured its performance using a c-index of 0.64. The c-index is a statistical measure that indicates how well a model can distinguish between patients who will and will not experience an outcome. A c-index of 0.5 means the model is no better than random chance, while a c-index of 1.0 means perfect prediction. A c-index of 0.64 indicates moderate predictive ability.\u003c\/p\u003e\n\n\u003cp\u003eThe result was statistically significant, with a P value of .005. This means there is only a 0.5% chance that this result occurred by random chance. The validation confirmed that the CCRS can stratify patients by their cumulative incidence of progression to a myeloid neoplasm.\u003c\/p\u003e\n\n\u003ch2 id=\"treatment\"\u003eTreatment Approaches and Outcomes\u003c\/h2\u003e\n\n\u003cp\u003eThe researchers noted that there is limited data available regarding treatment for CCUS. Because of this gap, they also discussed treatment approaches and outcomes for a subgroup of patients in the study who underwent therapy.\u003c\/p\u003e\n\n\u003cp\u003eThe study acknowledged that there is currently no established standard of care for CCUS. Existing therapies have low response rates. This is one reason why identifying high-risk patients is so important. High-risk patients may be appropriate candidates for clinical trials testing new treatments aimed at preventing or delaying disease progression.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThe CCRS is a practical and easily calculable tool that doctors can use to assess a patient's risk of CCUS progressing to a myeloid neoplasm. It uses only three factors: whether the patient has splicing mutations, whether their platelet count is below 100×10⁹\/L, and whether they have two or more mutations.\u003c\/p\u003e\n\n\u003cp\u003eThis risk score has several important implications for patient care:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePersonalized risk assessment:\u003c\/strong\u003e Doctors can calculate a patient's CCRS score using information from standard blood tests and genetic testing that is already part of the CCUS diagnostic process.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eInformed monitoring:\u003c\/strong\u003e Patients at higher risk may need more frequent monitoring and follow-up appointments.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eClinical trial eligibility:\u003c\/strong\u003e The CCRS can help identify high-risk patients who should be considered for clinical trials testing new treatments.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTreatment planning:\u003c\/strong\u003e Understanding a patient's risk level can help doctors and patients make more informed decisions about when to consider treatment.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe study underscores the importance of integrating clinical data (such as blood counts) with molecular data (such as mutation analysis) to assess the risk of CCUS progression. Neither type of information alone provides as complete a picture as the two combined.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers believe these findings are clinically relevant and will help shape management strategies for CCUS. The CCRS also can inform the design of future clinical trials by helping researchers identify appropriate patients to enroll.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations of the Study\u003c\/h2\u003e\n\n\u003cp\u003eThis study has several limitations that patients and doctors should consider.\u003c\/p\u003e\n\n\u003cp\u003eFirst, the study was conducted at academic medical centers, which may see patients with more complex or severe conditions than community hospitals. The results might differ in other healthcare settings.\u003c\/p\u003e\n\n\u003cp\u003eSecond, the validation cohort from the University of Pavia included 104 patients, which is smaller than the original group of 357 patients. A larger validation group would provide stronger confirmation of the risk score's accuracy.\u003c\/p\u003e\n\n\u003cp\u003eThird, the c-index of 0.64 in the validation group indicates moderate predictive ability, not perfect prediction. This means the CCRS is useful but cannot predict with certainty which individual patients will progress.\u003c\/p\u003e\n\n\u003cp\u003eFourth, the study followed patients for a limited time. Longer follow-up would provide more information about the long-term outcomes of patients with CCUS.\u003c\/p\u003e\n\n\u003cp\u003eFifth, there is limited data on treatment outcomes for CCUS. The researchers discussed treatment approaches for a subgroup of patients, but larger studies are needed to determine the best treatment strategies.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\n\u003cp\u003eIf you have been diagnosed with CCUS, here are some steps to consider:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk your doctor about your CCRS score.\u003c\/strong\u003e Your doctor can calculate this score using your blood test results and genetic testing results. Understanding your risk level can help guide your care.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiscuss your mutation profile.\u003c\/strong\u003e Ask whether you have splicing mutations and how many mutations were found. These factors affect your risk level.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMonitor your platelet count.\u003c\/strong\u003e A platelet count below 100×10⁹\/L is one of the three risk factors in the CCRS. Regular blood tests can track this.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about appropriate monitoring frequency.\u003c\/strong\u003e Patients at higher risk may need more frequent follow-up visits and blood tests.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eInquire about clinical trials.\u003c\/strong\u003e If you are in the high-risk group, ask your doctor whether any clinical trials are available that might be appropriate for you.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSeek care at a center experienced with CCUS.\u003c\/strong\u003e Academic medical centers that participate in research consortia like the CCUS consortium may have more experience with this condition.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStay informed.\u003c\/strong\u003e Research on CCUS is ongoing. New findings may change how doctors assess and manage this condition over time.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eIt is important to remember that a CCUS diagnosis does not mean you will definitely develop blood cancer. Even in the high-risk group, 62.8% of patients did not progress to a myeloid neoplasm within 2 years. The CCRS helps doctors identify who needs closer monitoring and who might benefit from early intervention, but it cannot predict any individual patient's outcome with certainty.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is clonal cytopenia of undetermined significance (CCUS)?\u003c\/h3\u003e\n\u003cp\u003eCCUS is a blood condition between normal aging and blood cancer. Patients have unexplained low blood cell counts plus a myeloid-related somatic mutation with a variant allele fraction of at least 2%. It does not meet the criteria for a myeloid neoplasm. Related conditions include CHIP, which has normal blood counts, and CMUS, which involves elevated monocytes.\u003c\/p\u003e\n\u003ch3\u003eWhat is the Clonal Cytopenia Risk Score (CCRS) and what does it measure?\u003c\/h3\u003e\n\u003cp\u003eThe CCRS is a tool that estimates the risk of CCUS progressing to a myeloid neoplasm. It uses three factors: splicing mutations (2 points), platelet count below 100×10⁹\/L (2.5 points), and two or more mutations (3 points). Scores sort patients into low, intermediate, and high risk. It was developed from 357 patients and validated in 104.\u003c\/p\u003e\n\u003ch3\u003eWhat do the low, intermediate, and high CCRS risk groups mean for progression?\u003c\/h3\u003e\n\u003cp\u003eOver two years, progression to a myeloid neoplasm occurred in 6.4% of low-risk patients, 14.1% of intermediate-risk patients, and 37.2% of high-risk patients. These differences were statistically significant. Even in the high-risk group, 62.8% did not progress within two years. The score estimates risk but cannot predict any individual patient's outcome with certainty.\u003c\/p\u003e\n\u003ch3\u003eHow is the CCRS calculated and what information is needed?\u003c\/h3\u003e\n\u003cp\u003eThe CCRS is calculated from information already part of the CCUS diagnostic process: whether you have splicing mutations, whether your platelet count is below 100×10⁹\/L, and whether you have two or more mutations. Your doctor can calculate it using standard blood test results and genetic testing results. No additional tests are required beyond those used to diagnose CCUS.\u003c\/p\u003e\n\u003ch3\u003eIf I have CCUS, what monitoring or follow-up might I need?\u003c\/h3\u003e\n\u003cp\u003ePatients at higher risk may need more frequent monitoring and follow-up appointments. Regular blood tests can track your platelet count, since a count below 100×10⁹\/L is one of the three risk factors. Ask your doctor about the appropriate monitoring frequency for your risk level. The CCRS can help guide these decisions.\u003c\/p\u003e\n\u003ch3\u003eAre there clinical trials for CCUS, and who might be eligible?\u003c\/h3\u003e\n\u003cp\u003eThere is currently no established standard of care for treating CCUS, and existing therapies have low response rates. High-risk patients may be appropriate candidates for clinical trials testing new treatments aimed at preventing or delaying progression. If you are in the high-risk group, ask your doctor whether any clinical trials are available that might be appropriate for you.\u003c\/p\u003e\n\u003ch3\u003eDoes a CCUS diagnosis mean I will definitely develop blood cancer?\u003c\/h3\u003e\n\u003cp\u003eNo. A CCUS diagnosis does not mean you will definitely develop blood cancer. Even in the high-risk group, 62.8% of patients did not progress to a myeloid neoplasm within two years. The CCRS helps doctors identify who needs closer monitoring and who might benefit from early intervention, but it cannot predict any individual patient's outcome with certainty.\u003c\/p\u003e\n\u003ch3\u003eI was just diagnosed with clonal cytopenia of undetermined significance (CCUS) — when should I seek a second opinion?\u003c\/h3\u003e\n\u003cp\u003eA second opinion can be useful when a CCRS score is calculated, since the score depends on whether splicing mutations are present, whether the platelet count is below 100×10⁹\/L, and whether two or more mutations were found. A score of 5 points or higher places a patient in the high-risk group, with a 37.2% two-year progression risk, and may prompt consideration of clinical trials. Reviewing the mutation profile and blood counts with an independent expert can help confirm risk level and monitoring plans. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Risk prediction for clonal cytopenia: multicenter real-world evidence\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Zhuoer Xie, Rami S. Komrokji, Najla Al‐Ali, Alexandra Regelson, Susan Michelle Geyer, Anand Ashwin Patel, et al.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Blood, Volume 144, Issue 19\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication date:\u003c\/strong\u003e November 7, 2024\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.1182\/blood.2024024756\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eStudy funding and disclosures:\u003c\/strong\u003e The authors reported numerous financial relationships with pharmaceutical companies, including honoraria, consulting fees, advisory board memberships, and research funding. These relationships are disclosed in the original article. All other authors reported no relevant conflicts of interest.\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and should not replace discussion with your healthcare provider. Always consult your doctor about your individual medical situation.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47816827633820,"sku":null,"price":0.0,"currency_code":"KRW","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0599\/5449\/5644\/files\/ddn-medical-article-new-risk-score-helps-predict-which-patients-with-clonal-cytopenia-will-develop-blood-cancer-hero.png?v=1792995745","url":"https:\/\/diagnosticdetectives.kr\/products\/new-risk-score-helps-predict-which-patients-with-clonal-cytopenia-will-develop-blood-cancer","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}